Markets:

Overview

News

Currencies

International

Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.03 +0.30 (+1.79%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 Next >

Purple, Bausch + Lomb, Etsy, Intel, and Camping World Shares Are Falling, What You Need To Know

August 21, 2025

A number of stocks fell in the afternoon session after markets continued to decline, as investors grew cautious ahead of a key speech by Federal Reserve Chair Jerome Powell. The move came as U.S....

Via StockStory

Topics Economy Stocks

Medical Devices & Supplies - Specialty Stocks Q2 Highlights: Bausch + Lomb (NYSE:BLCO)

August 20, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Bausch + Lomb...

Via StockStory

1 Safe-and-Steady Stock with Competitive Advantages and 2 That Underwhelm

August 15, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Examining the Future: Bausch & Lomb's Earnings Outlook ↗

July 29, 2025

Via Benzinga

Earnings Scheduled For April 30, 2025 ↗

April 30, 2025

Via Benzinga

Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Economy Lawsuit

BLCO Q2 Deep Dive: Product Launches Offset Margin Pressures, Management Highlights Pipeline Investments

August 12, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q2 CY2025, with sales up 5.1% year on year to $1.28 billion. The company’s full-year revenue guidance of $5.1 billion...

Via StockStory

1 Stock Under $50 to Target This Week and 2 We Ignore

August 07, 2025

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

3 Small-Cap Stocks with Warning Signs

August 06, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Bausch Lomb (BLCO) Q2 Revenue Rises 5% ↗

July 30, 2025

Via The Motley Fool

Why Bausch + Lomb (BLCO) Stock Is Down Today

July 30, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.1% in the morning session after the company reported mixed second-quarter 2025 financial results where a decline in profitability overshadowed...

Via StockStory

Topics Artificial Intelligence Initial Public Offering

Bausch + Lomb’s (NYSE:BLCO) Q2 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations

July 30, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 5.1% year on year to $1.28 billion. The company’s full-year revenue guidance...

Via StockStory

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout ↗

July 29, 2025

Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials.

Via Benzinga

Bausch + Lomb (BLCO) Q2 Earnings Report Preview: What To Look For

July 28, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before market hours. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Medical Devices & Supplies - Specialty Stocks Q1 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers

July 20, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Bausch + Lomb (NYSE:BLCO) and its peers.

Via StockStory

Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie ↗

July 18, 2025

This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant and Windsurf.

Via Benzinga

3 Value Stocks in Hot Water

June 10, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

3 Stocks Under $50 with Questionable Fundamentals

June 09, 2025

Via StockStory

3 of Wall Street’s Favorite Stocks with Mounting Challenges

June 05, 2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

1 Safe-and-Steady Stock for Long-Term Investors and 2 to Question

June 03, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 ↗

May 29, 2025

FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.

Via Benzinga

Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know

May 27, 2025

A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports,...

Via StockStory

Topics Government Stocks World Trade

Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90% ↗

May 16, 2025

Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He also trims exposure to Southwest Gas Holdings.

Via Benzinga

BLCO Q1 Earnings Call: Misses on Profit, Highlights Product Innovation and Tariff Uncertainty

May 14, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) fell short of the market’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year...

Via StockStory

Topics World Trade

3 Profitable Stocks Walking a Fine Line

May 08, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Topics Economy Supply Chain

Why Bausch + Lomb (BLCO) Shares Are Falling Today

April 30, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 21.2% in the morning session after the company reported weak first quarter 2025 results: constant currency revenue fell short of Wall Street's...

Via StockStory

Topics Initial Public Offering

Wednesday's session: gap up and gap down stocks ↗

April 30, 2025

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Starbucks Posts Weak Earnings, Joins Super Micro Computer, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

April 30, 2025

Via Benzinga

Bausch + Lomb (NYSE:BLCO) Misses Q1 Sales Targets, Stock Drops 10.4%

April 30, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year revenue...

Via StockStory

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bausch + Lomb Corporation Common Shares (NY:BLCO)

Headline News about Bausch + Lomb Corporation Common Shares

Starting at $3.75/week.

Subscribe Today